Related Experiment Video

Updated: Apr 10, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

[Hepatocardiac disorders : Interactions between two organ systems]

T Horvatits1, A Drolz2, K Rutter2

  • 1Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland. t.horvatits@uke.de.

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|June 14, 2015
PubMed

Insights

This article reviews cardiovascular complications in liver disease, including cirrhotic cardiomyopathy (CCMP) and portopulmonary hypertension (POPH). It also discusses hypoxic hepatitis (HH) and current medical therapies for these conditions.

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Liver disease frequently involves interactions between the hepatic portal and cardiovascular systems.
  • Cirrhotic cardiomyopathy (CCMP) presents as reduced cardiac function in cirrhosis, potentially masked by a hyperdynamic state.
  • Portopulmonary hypertension (POPH) is linked to portal hypertension and elevated mortality.

Purpose of the Study:

  • To provide an overview of cardiovascular complications in liver disease.
  • To define and discuss cirrhotic cardiomyopathy (CCMP), portopulmonary hypertension (POPH), and hypoxic hepatitis (HH).
  • To mention current therapeutic approaches for these conditions.

Main Methods:

  • Literature review of cardiovascular complications in liver disease.
  • Definition and description of CCMP, POPH, and HH.
  • Summary of existing medical therapies.

Main Results:

  • CCMP can present with reduced cardiac function masked by hyperdynamic circulation.
  • POPH is characterized by pulmonary arterial hypertension and portal hypertension, associated with high mortality.
  • Hypoxic hepatitis (HH) results from liver cell necrosis due to circulatory or respiratory failure.

Conclusions:

  • Cardiovascular complications are significant in liver disease patients.
  • Early recognition and management of CCMP, POPH, and HH are crucial.
  • Targeted therapies offer treatment options for these complex conditions.

Keywords:
Cardiac outputCardiomyopathiesHepatopulmonary syndromeLiver cirrhosisProstacyclin

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.6K

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
345
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
351
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
372
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
728